Why the study?
NO-synthase activity decreases in chronic heart failure, but supplying the myocardium with nitroxide donors such as DNIC-GSH may restore nitric oxide functions.
Does DNIC-GSH improve myocardial contractility in rats with doxorubicin-induced chronic heart failure?
Does DNIC-GSH improve myocardial contractility in rats with doxorubicin-induced chronic heart failure?
DNIC-GSH, a natural nitric oxide donor analogue, can restore myocardial relaxation and improve hemodynamics in a rat model of doxorubicin-induced severe chronic heart failure.
May support DNIC-GSH for LV relaxation in severe CHF models; leaves open contractility effects and human translation.
Activity of NO-synthases decreases in chronic heart failure (CHF), but restoration of nitric oxide (nitroxide) functions is possible when the myocardium is supplied with nitroxide donors. Of these, Dinitrosyl Iron Complex — Glutathione (DNIC-GSH) is the most promising drug. It is a synthesized analogue of natural compounds, i.e. dinitrosyl iron complexes formed in cells with various ligands. Objective. To study the effect of DNIC-GSH on myocardial contractility in rats with CHF that arose in 4—8 weeks after doxorubicin administration. Material and methods. We measured arterial and left ventricular (LV) pressure. Results. DNIC-GSH moderately reduced blood pressure and LV diastolic pressure, especially in rats with increased end-diastolic pressure in 8 weeks after doxorubicin injection. Acceleration of LV relaxation in these rats facilitated LV filling. Conclusion. DNIC-GSH can restore myocardial relaxation in case of severe CHF.
No takes yet. Share an insight, caveat, or question.
Lakomkin et al. (2024) studied Chronic heart failure (CHF) after doxorubicin administration. Dinitrosyl Iron Complex-Glutathione (DNIC-GSH) was evaluated on Arterial and left ventricular (LV) pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: